About Innate Pharma SA (OTCMKTS:IPHYF)
Innate Pharma S.A., a clinical-stage biotechnology company, discovers, develops, and sells immunotherapies for cancer and inflammatory diseases in France. The company offers Lirilumab (IPH2102/BMS-986015), a human checkpoint inhibitor, which is in Phase I/II clinical trial for squamous cell carcinoma of the head and neck, as well as in Phase I and Phase II clinical trials in various combinations to treat solid and hematologic tumors; Monalizumab, an immune checkpoint inhibitor that is in Phase I/II clinical trial to treat various cancer indications, as well as in Phase I clinical trial for the treatment of solid tumors; and IPH4102, an anti-KIR3DL2 humanized antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas. It is also involved in developing IPH4301, a humanized anti-MICA/B therapeutic antibody to treat oncology; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH33, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company has licensing agreements with Bristol-Myers Squibb, Novo Nordisk A/S, and the University of Genoa. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseille, France.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:IPHYF
- Previous Symbol: NASDAQ:IPHYF
- CUSIP: N/A
- Web: www.innate-pharma.com
Sales & Book Value:
- Annual Sales: $72.75 million
- Price / Sales: 7.60
- Cash Flow: $0.33 per share
- Price / Cash: 30.88
- Book Value: $1.77 per share
- Price / Book: 5.79
- Employees: 154
- Outstanding Shares: 53,920,000
Frequently Asked Questions for Innate Pharma SA (OTCMKTS:IPHYF)
What is Innate Pharma SA's stock symbol?
Innate Pharma SA trades on the OTCMKTS under the ticker symbol "IPHYF."
Who are some of Innate Pharma SA's key competitors?
Some companies that are related to Innate Pharma SA include Ignyta (RXDX), Delcath Systems (DCTHD), BioTelemetry (BEAT), Pharming Group NV (PHGUF), AxoGen (AXGN), Prometic Life Sciences (PFSCF), Consort Medical PLC Sponsored ADR (CSRMY), Triple-S Management Corporation (GTS), ARGENX SE-ADR (ARGX), Pharma Mar Sa (PHMMF), Zealand Pharma A/S (ZLDPF), Jounce Therapeutics (JNCE), Zealand Pharma A/S (ZEAL), Hanger (HNGR), Surmodics (SRDX), Oxford Biomedcl (OXBDF), Avadel Pharmaceuticals PLC. (AVDL) and Mirati Therapeutics (MRTX).
How do I buy Innate Pharma SA stock?
Shares of Innate Pharma SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innate Pharma SA's stock price today?
One share of Innate Pharma SA stock can currently be purchased for approximately $10.25.
How big of a company is Innate Pharma SA?
Innate Pharma SA has a market capitalization of $603.39 million and generates $72.75 million in revenue each year. Innate Pharma SA employs 154 workers across the globe.
How can I contact Innate Pharma SA?
Innate Pharma SA's mailing address is 117 Avenue de Luminy, Marseille I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]
MarketBeat Community Rating for Innate Pharma SA (OTCMKTS IPHYF)MarketBeat's community ratings are surveys of what our community members think about Innate Pharma SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Innate Pharma SA (OTCMKTS:IPHYF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Innate Pharma SA (OTCMKTS:IPHYF)
Analysts' Ratings History for Innate Pharma SA (OTCMKTS:IPHYF)
(Data available from 11/18/2015 forward)
|8/30/2017||HC Wainwright||Reiterated Rating||Buy|
|12/5/2016||Leerink Swann||Reiterated Rating||Buy|
Earnings History for Innate Pharma SA (OTCMKTS:IPHYF)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Innate Pharma SA (OTCMKTS:IPHYF)
Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.84 EPS
Dividend History for Innate Pharma SA (OTCMKTS:IPHYF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Innate Pharma SA (OTCMKTS IPHYF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Innate Pharma SA (OTCMKTS:IPHYF)
Latest Headlines for Innate Pharma SA (OTCMKTS IPHYF)
No headlines for this company have been tracked by MarketBeat.com
Financials are not available for this stock.
Innate Pharma SA (OTCMKTS IPHYF) Chart for Saturday, November, 18, 2017